Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously tre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Appl Health Econ Health Policy
Main Authors: Peters, Michel L., de Meijer, Claudine, Wyndaele, Dirk, Noordzij, Walter, Leliveld-Kors, Annemarie M., van den Bosch, Joan, van den Berg, Pieter H., Baka, Agni, Gaultney, Jennifer G.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2017
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797195/
https://ncbi.nlm.nih.gov/pubmed/28866822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40258-017-0350-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados